Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate pomalidomide across diverse oncological and hematological indications, focusing heavily on relapsed and refractory multiple myeloma, diffuse large B-cell lymphoma, and virus-associated malignancies such as Kaposi sarcoma. Sponsored by government organizations like the National Cancer Institute, academic centers, and pharmaceutical companies including Janssen and AbbVie, these studies exhibit a range of statuses, including recruiting, active non-recruiting, completed, and terminated.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05259839 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Multiple Myeloma |
AbbVie |
2022-10-20 | PHASE1 |
| NCT05730036 | RECRUITING | Relapsed Refractory Multiple Myeloma (RRMM) |
Regeneron Pharmaceuticals |
2023-09-18 | PHASE3 |
| NCT07748689 | NOT_YET_RECRUITING | Relapsed / Refractory Multiple Myeloma |
Polish Myeloma Consortium |
2026-10 | PHASE2 |
| NCT07728188 | NOT_YET_RECRUITING | Relapsed or Refractory Multiple Myeloma |
AbbVie |
2026-11-30 | PHASE3 |
| NCT06953960 | RECRUITING | Multiple Myeloma |
AbbVie |
2025-07-23 | PHASE1; PHASE2 |
| NCT07227311 | RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2026-04-15 | PHASE2 |
| NCT07720843 | NOT_YET_RECRUITING | Relapse Multiple Myeloma; Refractory Multiple Myeloma |
Montefiore Medical Center |
2026-09-01 | PHASE1 |
| NCT07749365 | RECRUITING | DLBCL - Diffuse Large B Cell Lymphoma; PCNSL (Primary CNS Lymphoma) |
The First Affiliated Hospital of Xiamen University |
2026-07-25 | PHASE2 |
| NCT07096778 | RECRUITING | Multiple Myeloma Refractory; Multiple Myeloma in Relapse |
CellCentric Ltd. |
2026-01-22 | PHASE2 |
| NCT07772024 | RECRUITING | Multiple Myeloma Refractory; Multiple Myeloma in Relapse |
CellCentric Ltd. |
2026-08 | PHASE3 |
| NCT07623798 | NOT_YET_RECRUITING | Relapsed or Refractory Multiple Myeloma |
Innovent Biologics (Suzhou) Co. Ltd. |
2026-06-05 | PHASE3 |
| NCT07222761 | RECRUITING | Relapsed and/or Refractory Multiple Myeloma (RRMM) |
Regeneron Pharmaceuticals |
2026-01-02 | PHASE3 |
| NCT07463807 | RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2027-04-12 | PHASE1; PHASE2 |
| NCT07452198 | RECRUITING | Multiple Myeloma |
Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
2026-03-09 | PHASE3 |
| NCT05438043 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2022-12-15 | PHASE3 |
| NCT07579234 | RECRUITING | Relapsed or Refractory Multiple Myeloma (RRMM) |
Shandong New Time Pharmaceutical Co., LTD |
2026-01-25 | PHASE3 |
| NCT06768489 | RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2024-12-04 | PHASE1 |
| NCT07757412 | NOT_YET_RECRUITING | Multiple Myeloma Progression |
Odense University Hospital |
2026-09-01 | PHASE2 |
| NCT05922501 | RECRUITING | Relapsed Cancer; Refractory Multiple Myeloma; Multiple Myeloma |
Massachusetts General Hospital |
2024-05-31 | PHASE2 |
| NCT04910568 | RECRUITING | Multiple Myeloma |
Genentech, Inc. |
2021-07-26 | PHASE1 |
| NCT07569757 | NOT_YET_RECRUITING | Multiple Myeloma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2026-06 | PHASE3 |
| NCT05669989 | ENROLLING_BY_INVITATION | Plasma Cell Myeloma |
Sanofi |
2023-04-05 | PHASE2 |
| NCT07555938 | RECRUITING | Multiple Myeloma |
Hoffmann-La Roche |
2026-06-23 | PHASE3 |
| NCT05714839 | RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2023-06-14 | PHASE1; PHASE2 |
| NCT07257510 | RECRUITING | Mantle Cell Lymphoma (MCL); POZ |
Peking University Third Hospital |
2025-08-01 | |
| NCT05789303 | RECRUITING | Multiple Myeloma; Relapse Multiple Myeloma |
University of Chicago |
2023-05-30 | PHASE2 |
| NCT07742215 | RECRUITING | Myeloma Multiple |
Biocad |
2026-06-15 | PHASE3 |
| NCT07760610 | NOT_YET_RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
The First Hospital of Jilin University |
2026-09 | PHASE4 |
| NCT06413498 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Kite, A Gilead Company |
2024-08-23 | PHASE3 |
| NCT07391657 | RECRUITING | Relapsed Refractory Multiple Myeloma |
AstraZeneca |
2026-02-23 | PHASE3 |
| NCT05389423 | RECRUITING | Diffuse Large Cell Lymphoma; Non-Hodgkin Lymphoma; Burkitt Lymphoma; Plasmablastic Lymphoma; B-Cell Neoplasm |
National Cancer Institute (NCI) |
2023-06-27 | PHASE1 |
| NCT07560449 | NOT_YET_RECRUITING | Malignant Plasma Cell Neoplasms |
Qilu Pharmaceutical Co., Ltd. |
2026-06 | PHASE2 |
| NCT07523737 | RECRUITING | Primary Central Nervous System Lymphoma (PCNSL); Diffuse Large B Cell Lymphoma (DLBCL) |
Beijing Tongren Hospital |
2026-04-01 | PHASE2 |
| NCT05137054 | RECRUITING | Multiple Myeloma |
Regeneron Pharmaceuticals |
2022-08-17 | PHASE1 |
| NCT06879379 | RECRUITING | Multiple Myeloma, Newly Diagnosed |
Peking University People's Hospital |
2025-03 | PHASE2; PHASE3 |
| NCT06948084 | NOT_YET_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2026-08-26 | PHASE2 |
| NCT02659930 | ACTIVE_NOT_RECRUITING | Kaposi Sarcoma |
National Cancer Institute (NCI) |
2016-01-13 | PHASE1 |
| NCT05651932 | RECRUITING | Multiple Myeloma; Myeloma; Myeloma Multiple |
K36 Therapeutics, Inc. |
2023-02-22 | PHASE1 |
| NCT06615479 | RECRUITING | Relapsed or Refractory Multiple Myeloma (RRMM) |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2025-03-12 | PHASE3 |
| NCT07441954 | NOT_YET_RECRUITING | Indolent Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2026-03-20 | PHASE1; PHASE2 |
| NCT06158841 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
AbbVie |
2024-05-19 | PHASE3 |
| NCT07138209 | RECRUITING | Relapsed or Refractory Multiple Myeloma |
Qilu Pharmaceutical Co., Ltd. |
2025-11-07 | PHASE3 |
| NCT06742138 | NOT_YET_RECRUITING | Multiple Myeloma |
Qilu Pharmaceutical Co., Ltd. |
2025-01 | PHASE3 |
| NCT07018050 | RECRUITING | Relapsed or Refractory Multiple Myeloma |
Qilu Pharmaceutical Co., Ltd. |
2025-09-12 | PHASE2 |
| NCT05208307 | RECRUITING | Plasma Cell Myeloma |
Emory University |
2022-07-21 | PHASE2 |
| NCT04850599 | ACTIVE_NOT_RECRUITING | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
OHSU Knight Cancer Institute |
2022-06-14 | PHASE2 |
| NCT05556798 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2022-10-04 | PHASE1 |
| NCT07532525 | RECRUITING | Recurrent B Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory B-Cell Non-Hodgkin Lymphoma |
University of Michigan Rogel Cancer Center |
2026-09-01 | PHASE1 |
| NCT04643002 | RECRUITING | Plasma Cell Myeloma Refractory |
Sanofi |
2021-01-25 | PHASE1; PHASE2 |
| NCT04790474 | ACTIVE_NOT_RECRUITING | Multiple Myeloma in Relapse; Refractory Multiple Myeloma |
Tel-Aviv Sourasky Medical Center |
2021-03-25 | PHASE2 |
| NCT05451771 | ACTIVE_NOT_RECRUITING | AL Amyloidosis |
Columbia University |
2022-10-26 | PHASE1; PHASE2 |
| NCT06106945 | RECRUITING | Multiple Myeloma |
AstraZeneca |
2023-12-05 | PHASE1; PHASE2 |
| NCT06464991 | RECRUITING | Multiple Myeloma |
Nanjing IASO Biotechnology Co., Ltd. |
2024-03-27 | PHASE3 |
| NCT05455320 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2022-10-13 | PHASE3 |
| NCT04124497 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Deletion 17P Syndrome |
Fondazione EMN Italy Onlus |
2019-07-01 | PHASE2 |
| NCT07072208 | RECRUITING | Diffuse Large B-Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2024-11-01 | |
| NCT04176718 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse; Relapse |
Andrew Yee, MD |
2020-05-18 | PHASE2 |
| NCT04108195 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2020-02-21 | PHASE1 |
| NCT04835129 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Medical College of Wisconsin |
2022-01-10 | PHASE2 |
| NCT02343042 | RECRUITING | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-10 | PHASE1; PHASE2 |
| NCT04068597 | RECRUITING | Haematological Malignancy; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Multiple Myeloma; Higher-risk Myelodysplastic Syndrome; Peripheral T Cell Lymphoma |
CellCentric Ltd. |
2019-08-09 | PHASE1; PHASE2 |
| NCT06508983 | RECRUITING | Relapsed/Refractory Multiple Myeloma |
Hangzhou Sumgen Biotech Co., Ltd. |
2024-06-14 | PHASE3 |
| NCT06660498 | ACTIVE_NOT_RECRUITING | HIV-1 Infection |
University of Aarhus |
2025-05-13 | PHASE1; PHASE2 |
| NCT04508790 | RECRUITING | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
City of Hope Medical Center |
2020-11-24 | PHASE2 |
| NCT04661137 | SUSPENDED | Multiple Myeloma |
Hackensack Meridian Health |
2021-03-16 | PHASE2 |
| NCT05519085 | RECRUITING | Relapsed or Refractory Multiple Myeloma |
Celgene |
2022-09-20 | PHASE3 |
| NCT04270175 | ACTIVE_NOT_RECRUITING | Amyloid; AL Amyloidosis; Refractory AL Amyloidosis |
Weill Medical College of Cornell University |
2021-04-14 | PHASE2 |
| NCT06924424 | ACTIVE_NOT_RECRUITING | Multiple Myeloma, Neoplasms |
Peking University People's Hospital |
2025-03-01 | |
| NCT04883242 | ACTIVE_NOT_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
University of Washington |
2021-07-29 | PHASE2 |
| NCT05183139 | WITHDRAWN | Multiple Myeloma |
Takeda |
2022-06-30 | PHASE4 |
| NCT04902443 | RECRUITING | Viral Associated Malignancies; Kaposi Sarcoma; EBV/KSHV-associated Lymphomas |
National Cancer Institute (NCI) |
2021-12-10 | PHASE1 |
| NCT06855823 | RECRUITING | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) |
Sun Yat-sen University |
2025-01-14 | PHASE1; PHASE2 |
| NCT06342466 | RECRUITING | Systemic Amyloidosis |
Jin Lu, MD |
2024-05-06 | PHASE2 |
| NCT02718833 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Massachusetts General Hospital |
2016-06-21 | PHASE2 |
| NCT01562405 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Massachusetts General Hospital |
2012-05 | PHASE1 |
| NCT04973605 | RECRUITING | Relapsed/Refractory Multiple Myeloma |
BeOne Medicines |
2021-09-16 | PHASE1; PHASE2 |
| NCT05581875 | NOT_YET_RECRUITING | Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasms; Gammopathy, Monoclonal; Paraproteinemias; Blood Protein Disorders; Haematologic Disease; Corneal Disease; Neoplasms, Plasma Cell |
Hellenic Society of Hematology |
2022-10-20 | PHASE1; PHASE2 |
| NCT04577755 | ACTIVE_NOT_RECRUITING | Skin Kaposi Sarcoma |
National Cancer Institute (NCI) |
2022-03-18 | PHASE2 |
| NCT07015021 | NOT_YET_RECRUITING | Multiple Myeloma; Carfilzomib; Daratumumab; Pomalidomide |
The First Affiliated Hospital of Soochow University |
2025-06-01 | |
| NCT06554561 | RECRUITING | PCNSL |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2024-08-31 | PHASE1; PHASE2 |
| NCT06152575 | RECRUITING | Multiple Myeloma |
Pfizer |
2024-02-08 | PHASE3 |
| NCT03539744 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
AbbVie |
2018-10-22 | PHASE3 |
| NCT04764942 | ACTIVE_NOT_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
Mayo Clinic |
2021-05-06 | PHASE1; PHASE2 |
| NCT03651128 | COMPLETED | Multiple Myeloma |
Celgene |
2019-04-16 | PHASE3 |
| NCT06208150 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2024-01-22 | PHASE3 |
| NCT03984097 | COMPLETED | Multiple Myeloma |
Takeda |
2019-07-29 | PHASE1 |
| NCT05028348 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
European Myeloma Network B.V. |
2022-04-19 | PHASE3 |
| NCT05066607 | UNKNOWN | AL Amyloidosis |
Intergroupe Francophone du Myelome |
2022-02-11 | PHASE2 |
| NCT05020236 | RECRUITING | Multiple Myeloma |
Pfizer |
2021-10-04 | PHASE3 |
| NCT02719613 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2016-07-15 | PHASE2 |
| NCT06484829 | RECRUITING | Relapsed or Refractory Multiple Myeloma (RRMM) |
Chengdu Zenitar Biomedical Technology Co., Ltd |
2024-03-25 | PHASE1; PHASE2 |
| NCT06376214 | RECRUITING | Light Chain (AL) Amyloidosis |
Nanjing University School of Medicine |
2023-01-01 | |
| NCT04941937 | UNKNOWN | Multiple Myeloma |
Juan Du |
2022-01-27 | PHASE2 |
| NCT05050305 | WITHDRAWN | Multiple Myeloma; Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Dana-Farber Cancer Institute |
2024-03 | PHASE2 |
| NCT06232707 | WITHDRAWN | Multiple Myeloma |
Celgene |
2024-05-03 | PHASE3 |
| NCT01665794 | COMPLETED | Multiple Myeloma |
University of Chicago |
2012-08-13 | PHASE1; PHASE2 |
| NCT05298683 | UNKNOWN | Multiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases |
Hellenic Society of Hematology |
2022-05 | PHASE2 |
| NCT05572515 | ACTIVE_NOT_RECRUITING | Relapsed or Refractory Multiple Myeloma |
Janssen Research & Development, LLC |
2023-03-29 | PHASE3 |
| NCT04722146 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-03-12 | PHASE1 |
| NCT05408026 | WITHDRAWN | Relapsed or Refractory Multiple Myeloma |
Alliance Foundation Trials, LLC. |
2022-10-01 | PHASE1; PHASE2 |
| NCT05083169 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-10-14 | PHASE3 |
| NCT01745588 | COMPLETED | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2012-12 | PHASE2 |
| NCT06832228 | UNKNOWN | Diffuse Large B-cell Lymphoma (DLBCL) |
Zhejiang Cancer Hospital |
2024-09-01 | |
| NCT02542657 | ACTIVE_NOT_RECRUITING | Myeloma |
Joseph Tuscano |
2015-10 | PHASE1; PHASE2 |
| NCT05809180 | UNKNOWN | Diffuse Large B Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2023-01-04 | |
| NCT03590652 | TERMINATED | Relapsed/Refractory Multiple Myeloma |
University of California, San Diego |
2018-10-17 | PHASE2 |
| NCT03756896 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma |
Emory University |
2019-01-25 | PHASE2 |
| NCT05911321 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Relapse; Refractory; Aging; Co-morbidity |
UNC Lineberger Comprehensive Cancer Center |
2023-12-05 | PHASE2 |
| NCT06255847 | UNKNOWN | Multiple Myeloma in Relapse |
Shanxi Bethune Hospital |
2022-06-15 | PHASE2 |
| NCT05348213 | RECRUITING | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2022-05-16 | PHASE2 |
| NCT03715478 | ACTIVE_NOT_RECRUITING | Relapsed and/or Refractory Multiple Myeloma |
Canadian Myeloma Research Group |
2018-11-26 | PHASE1; PHASE2 |
| NCT04094961 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Multiple Myeloma in Relapse |
Omar Nadeem, MD |
2019-09-18 | PHASE1; PHASE2 |
| NCT05378971 | UNKNOWN | Multiple Myeloma |
LanZhou University |
2022-05-15 | |
| NCT01198067 | TERMINATED | Recurrent Waldenstrom Macroglobulinemia; Refractory Waldenstrom Macroglobulinemia |
M.D. Anderson Cancer Center |
2010-10-06 | PHASE1 |
| NCT01946477 | COMPLETED | Multiple Myeloma |
Celgene |
2014-05-29 | PHASE2 |
| NCT07150104 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2022-08-31 | PHASE1; PHASE2 |
| NCT04126200 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2019-10-07 | PHASE1; PHASE2 |
| NCT04287855 | UNKNOWN | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Poitiers University Hospital |
2020-08-28 | PHASE2 |
| NCT05050097 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-09-22 | PHASE1 |
| NCT05675319 | TERMINATED | Multiple Myeloma |
Universitätsklinikum Hamburg-Eppendorf |
2023-03-03 | PHASE3 |
| NCT07694011 | COMPLETED | Pomalidomide Bioequivalence Study in Healthy Volunteers |
Knight Therapeutics (USA) Inc |
2025-01-25 | PHASE1 |
| NCT06455748 | UNKNOWN | Amyloid Light-chain Amyloidosis |
Yongyong MA |
2024-03-01 | |
| NCT03732703 | COMPLETED | Relapsed Refractory Multiple Myeloma |
Multiple Myeloma Research Consortium |
2019-04-01 | PHASE1; PHASE2 |
| NCT04895917 | TERMINATED | AL Amyloidosis |
Fondazione IRCCS Policlinico San Matteo di Pavia |
2021-06-23 | PHASE2 |
| NCT03601806 | COMPLETED | Human Immunodeficiency Virus 1 Positive; Skin Kaposi Sarcoma |
AIDS Malignancy Consortium |
2021-04-26 | PHASE2 |
| NCT04802161 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Post Cytotoxic Therapy; Acute Myeloid Leukemia With Multilineage Dysplasia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm |
National Cancer Institute (NCI) |
2022-08-24 | PHASE2 |
| NCT06058689 | UNKNOWN | Bioequivalence Study |
Megalabs |
2024-09-15 | PHASE1 |
| NCT05405166 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma Recurrent |
Sanofi |
2022-06-23 | PHASE3 |
| NCT05931328 | RECRUITING | Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2022-10-15 | PHASE2 |
| NCT04150965 | TERMINATED | Multiple Myeloma; Relapsed Refractory Multiple Myeloma |
Multiple Myeloma Research Consortium |
2020-07-10 | PHASE1; PHASE2 |
| NCT04925193 | ACTIVE_NOT_RECRUITING | Multiple Myeloma in Relapse |
University of Colorado, Denver |
2021-11-18 | PHASE2 |
| NCT04989140 | UNKNOWN | Multiple Myeloma |
Peking Union Medical College Hospital |
2021-07-26 | PHASE4 |
| NCT05478993 | UNKNOWN | Multiple Myeloma |
Peking University People's Hospital |
2022-10-12 | PHASE2 |
| NCT05509374 | UNKNOWN | Multiple Myeloma |
Samsung Medical Center |
2021-10-28 | PHASE2 |
| NCT05556616 | TERMINATED | Multiple Myeloma |
Teva Branded Pharmaceutical Products R&D LLC |
2023-01-12 | PHASE1 |
| NCT02400242 | TERMINATED | Multiple Myeloma |
Celgene |
2015-05-07 | PHASE1 |
| NCT04302324 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Refractory Multiple Myeloma; Relapse Multiple Myeloma |
Weill Medical College of Cornell University |
2021-10-28 | PHASE2 |
| NCT06956170 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2022-02-10 | PHASE3 |
| NCT04181827 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2020-06-12 | PHASE3 |
| NCT04892446 | TERMINATED | Multiple Myeloma |
Gilead Sciences |
2021-11-09 | PHASE2 |
| NCT03731832 | COMPLETED | Refractory Multiple Myeloma |
GWT-TUD GmbH |
2018-09-20 | PHASE2 |
| NCT05390749 | UNKNOWN | Primary Central Nervous System Lymphoma |
Peking Union Medical College Hospital |
2022-04-11 | PHASE2 |
| NCT01644110 | COMPLETED | Primary Myelofibrosis; Secondary Myelofibrosis; PMF; SMF; Post-PV MF; Post-ET MF |
University of Ulm |
2013-08 | PHASE1; PHASE2 |
| NCT04045795 | COMPLETED | Multiple Myeloma |
Sanofi |
2019-08-06 | PHASE1 |
| NCT01997840 | TERMINATED | Multiple Myeloma |
Celgene |
2014-03-01 | PHASE1; PHASE2 |
| NCT05288062 | TERMINATED | Plasma Cell Myeloma; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma; Smoldering Plasma Cell Myeloma |
Mayo Clinic |
2022-06-15 | PHASE2 |
| NCT03713294 | COMPLETED | Refractory Plasma Cell Myeloma |
Mayo Clinic |
2019-01-14 | PHASE2 |
| NCT05555329 | COMPLETED | Multiple Myeloma in Relapse; Multiple Myeloma; Multiple Myeloma, Refractory |
Amsterdam UMC, location VUmc |
2022-12-01 | PHASE4 |
| NCT04484623 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2020-10-01 | PHASE3 |
| NCT03269136 | COMPLETED | Multiple Myeloma |
Pfizer |
2017-11-29 | PHASE1 |
| NCT05432414 | UNKNOWN | Multiple Myeloma |
RenJi Hospital |
2022-12-08 | PHASE2 |
| NCT04584307 | WITHDRAWN | Multiple Myeloma |
Natalie Callendar |
2021-04 | PHASE2 |
| NCT04700176 | TERMINATED | Multiple Myeloma |
Hackensack Meridian Health |
2022-05-02 | PHASE2 |
| NCT04392648 | WITHDRAWN | Relapsed and/or Refractory Multiple Myeloma |
Teva Branded Pharmaceutical Products R&D LLC |
2020-06-24 | PHASE1 |
| NCT03582033 | TERMINATED | Multiple Myeloma |
Seagen Inc. |
2018-11-01 | PHASE1 |
| NCT03257631 | COMPLETED | Central Nervous System Neoplasms; Medulloblastoma |
Celgene |
2017-09-18 | PHASE2 |
| NCT03910244 | COMPLETED | Telangiectasia, Hereditary Hemorrhagic |
The Cleveland Clinic |
2019-10-17 | PHASE2 |
| NCT05205252 | WITHDRAWN | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Epizyme, Inc. |
2021-12-22 | PHASE1; PHASE2 |
| NCT04355039 | WITHDRAWN | Refractory Multiple Myeloma; Relapse Multiple Myeloma |
Medical College of Wisconsin |
2021-07-01 | PHASE1 |
| NCT03287908 | TERMINATED | Relapsed/Refractory Multiple Myeloma |
Amgen |
2017-11-13 | PHASE1 |
| NCT03828292 | COMPLETED | Multiple Myeloma |
GlaxoSmithKline |
2019-03-14 | PHASE1 |
| NCT03683277 | TERMINATED | Multiple Myeloma; Relapsed and Refractory Multiple Myeloma; Genetic Condition |
Intergroupe Francophone du Myelome |
2019-11-03 | PHASE2 |
| NCT02406222 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Leeds |
2016-03 | PHASE2 |
| NCT04843579 | TERMINATED | Myeloma Multiple; Myeloma; Refractory Multiple Myeloma |
Weill Medical College of Cornell University |
2021-12-29 | PHASE2 |
| NCT04191616 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Amgen |
2020-08-06 | PHASE2 |
| NCT02939183 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Amgen |
2017-01-17 | PHASE1 |
| NCT03030261 | ACTIVE_NOT_RECRUITING | Multiple Myeloma in Relapse |
Washington University School of Medicine |
2017-11-22 | PHASE2 |
| NCT04162210 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2020-04-02 | PHASE3 |
| NCT03959358 | COMPLETED | Multiple Myeloma; Amyloidosis |
University Health Network, Toronto |
2020-07-03 | PHASE2 |
| NCT03215524 | COMPLETED | Multiple Myeloma |
Canadian Myeloma Research Group |
2017-10-25 | PHASE2 |
| NCT04895410 | TERMINATED | Multiple Myeloma |
AbbVie |
2022-01-17 | PHASE1 |
| NCT05236621 | UNKNOWN | Multiple Myeloma; Recurrent or Refractory |
Qilu Pharmaceutical Co., Ltd. |
2021-01-04 | PHASE3 |
| NCT01495598 | COMPLETED | Kaposi Sarcoma; Sarcoma, Kaposi |
National Cancer Institute (NCI) |
2012-01-10 | PHASE1; PHASE2 |
| NCT01734928 | COMPLETED | Multiple Myeloma |
Celgene |
2013-01-07 | PHASE3 |
| NCT04667663 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Cancer Trials Ireland |
2021-12-08 | PHASE1 |
| NCT02726581 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2016-08-10 | PHASE3 |
| NCT03143985 | COMPLETED | Multiple Myeloma |
Koen van Besien |
2017-07-21 | PHASE1 |
| NCT03841565 | WITHDRAWN | Recurrent Plasma Cell Myeloma |
Academic and Community Cancer Research United |
2020-08-07 | PHASE2 |
| NCT04762745 | UNKNOWN | Relapsed, Refractory, Multiple Myeloma |
Sun Yat-sen University |
2021-02 | PHASE1; PHASE2 |
| NCT03439280 | COMPLETED | Relapsed/Refractory; Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2018-04-20 | PHASE1; PHASE2 |
| NCT02807454 | TERMINATED | Multiple Myeloma |
Celgene |
2016-07-07 | PHASE2 |
| NCT03227432 | WITHDRAWN | Multiple Myeloma |
Dana-Farber Cancer Institute |
2018-12 | PHASE2 |
| NCT02004275 | UNKNOWN | Multiple Myeloma in Relapse |
Alliance for Clinical Trials in Oncology |
2014-02 | PHASE1; PHASE2 |
| NCT04902443 | Recruiting | Viral Associated Malignancies|Kaposi Sarcoma|EBV/KSHV-associated Lymphomas |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2021-12-10 | Phase 1 |
| NCT03657420 | WITHDRAWN | Multiple Myeloma |
Massachusetts General Hospital |
2019-05-30 | PHASE1 |
| NCT03015922 | UNKNOWN | Multiple Myeloma |
University of Leeds |
2017-06-05 | PHASE1 |
| NCT02283775 | COMPLETED | Plasma Cell Myeloma |
Sanofi |
2015-05-15 | PHASE1 |
| NCT03202628 | COMPLETED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Mayo Clinic |
2017-07-24 | PHASE2 |
| NCT02431208 | COMPLETED | Multiple Myeloma |
Hoffmann-La Roche |
2015-07-22 | PHASE1 |
| NCT03520985 | TERMINATED | Refractory Multiple Myeloma |
Swiss Cancer Institute |
2018-10-01 | PHASE2 |
| NCT03151811 | TERMINATED | Multiple Myeloma |
Oncopeptides AB |
2017-06-12 | PHASE3 |
| NCT03798314 | COMPLETED | Recurrent Nervous System Lymphoma; Recurrent Primary Vitreoretinal DLBCL; Refractory Nervous System Lymphoma; Refractory Primary Vitreoretinal DLBCL |
Mayo Clinic |
2019-01-30 | PHASE1 |
| NCT02569320 | COMPLETED | Recurrent Plasma Cell Myeloma |
Ohio State University Comprehensive Cancer Center |
2016-05-20 | PHASE1 |
| NCT02547662 | COMPLETED | Plasma Cell Leukemia; Plasma Cell Myeloma; Plasmacytoma |
Mayo Clinic |
2015-12-24 | PHASE2 |
| NCT02188368 | TERMINATED | Multiple Myeloma |
Oncotherapeutics |
2014-07-07 | PHASE2 |
| NCT02963493 | COMPLETED | Multiple Myeloma |
Oncopeptides AB |
2016-12-28 | PHASE2 |
| NCT01592370 | COMPLETED | Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma |
Bristol-Myers Squibb |
2012-08-02 | PHASE1; PHASE2 |
| NCT02294357 | TERMINATED | Multiple Myeloma |
Oncotherapeutics |
2014-12 | PHASE2 |
| NCT03170882 | COMPLETED | Relapsed and/or Refractory Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2017-08-01 | PHASE2 |
| NCT01421186 | COMPLETED | Multiple Myeloma |
MorphoSys AG |
2011-07 | PHASE1; PHASE2 |
| NCT03180736 | COMPLETED | Multiple Myeloma |
Stichting European Myeloma Network |
2017-06-14 | PHASE3 |
| NCT01464034 | TERMINATED | Multiple Myeloma |
Criterium, Inc. |
2011-11 | PHASE1; PHASE2 |
| NCT03567616 | TERMINATED | Multiple Myeloma |
AbbVie |
2018-10-18 | PHASE2 |
| NCT02029950 | COMPLETED | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia-2; High Risk Myelodysplastic Syndrome; Myeloproliferative Neoplasm |
National Cancer Institute (NCI) |
2013-12-16 | PHASE1 |
| NCT01946152 | TERMINATED | Multiple Myeloma-Light Chain Only; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
M.D. Anderson Cancer Center |
2014-03-05 | PHASE1; PHASE2 |
| NCT02626481 | COMPLETED | Multiple Myeloma |
University Hospital, Lille |
2015-12-28 | PHASE2 |
| NCT03440411 | TERMINATED | Multiple Myeloma |
Fondazione EMN Italy Onlus |
2016-02-18 | PHASE3 |
| NCT01712789 | COMPLETED | Multiple Myeloma |
Celgene |
2012-11-06 | PHASE3 |
| NCT02661022 | TERMINATED | Multiple Myeloma |
Stemline Therapeutics, Inc. |
2016-01 | PHASE1; PHASE2 |
| NCT03104270 | TERMINATED | Multiple Myeloma |
Oncotherapeutics |
2017-03-13 | PHASE2 |
| NCT02612779 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2016-02-09 | PHASE2 |
| NCT02336815 | COMPLETED | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-05-26 | PHASE2 |
| NCT01497093 | COMPLETED | Multiple Myeloma |
Celgene |
2012-02-15 | PHASE1 |
| NCT02415153 | COMPLETED | Neurofibromatosis Type 1; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Primary Central Nervous System Neoplasm; Refractory Primary Central Nervous System Neoplasm |
National Cancer Institute (NCI) |
2015-07-14 | PHASE1 |
| NCT02287558 | COMPLETED | Hereditary Hemorrhagic Telangiectasia; Idiopathic Vascular Ectasia |
The Cleveland Clinic |
2015-01-27 | PHASE1 |
| NCT04243109 | TERMINATED | Multiple Myeloma |
Maimónides Biomedical Research Institute of Córdoba |
2017-02-23 | PHASE2 |
| NCT02176213 | COMPLETED | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Ajai Chari |
2014-06 | PHASE2 |
| NCT01999335 | TERMINATED | Multiple Myeloma |
Amgen |
2014-07-30 | PHASE1 |
| NCT03242460 | COMPLETED | Relapsed and/or refractorY Multiple Myeloma |
Kosin University Gospel Hospital |
2015-05-12 | PHASE2 |
| NCT03113942 | UNKNOWN | High Grade Squamous Intra-epithelial Lesion (HSIL) |
Kirby Institute |
2017-06-14 | PHASE2 |
| NCT02265510 | TERMINATED | Solid Tumors; Advanced Malignancies; Metastatic Cancer |
Incyte Corporation |
2014-09-10 | PHASE1; PHASE2 |
| NCT01998971 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2014-02-18 | PHASE1 |
| NCT03601624 | UNKNOWN | Multiple Myeloma in Relapse; Multiple Myeloma Progression; Refractory Multiple Myeloma |
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado |
2018-09-01 | PHASE2 |
| NCT02616640 | COMPLETED | Multiple Myeloma |
Celgene |
2016-01-11 | PHASE1 |
| NCT02990338 | COMPLETED | Plasma Cell Myeloma |
Sanofi |
2016-12-22 | PHASE3 |
| NCT01570387 | COMPLETED | AL Amyloidosis |
Boston Medical Center |
2012-06 | PHASE1; PHASE2 |
| NCT01728259 | TERMINATED | Light Chain Deposition Disease; Primary Systemic Amyloidosis |
Barbara Ann Karmanos Cancer Institute |
2013-03 | PHASE1 |
| NCT01638936 | COMPLETED | Multiple Myeloma |
Biotest Pharmaceuticals Corporation |
2012-07-03 | PHASE1; PHASE2 |
| NCT01575925 | COMPLETED | Multiple Myeloma; Renal Impairment |
Celgene |
2012-06-01 | PHASE1 |
| NCT02576977 | TERMINATED | Multiple Myeloma |
Merck Sharp & Dohme LLC |
2015-10-19 | PHASE3 |
| NCT02548962 | TERMINATED | Multiple Myeloma |
Pharmacyclics LLC. |
2016-03 | PHASE1; PHASE2 |
| NCT03143049 | UNKNOWN | Relapse Multiple Myeloma |
National University Hospital, Singapore |
2017-09-13 | PHASE3 |
| NCT02916420 | UNKNOWN | Multiple Myeloma |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2016-09 | PHASE3 |
| NCT00946270 | COMPLETED | Polycythemia Vera; Thrombocythemia |
M.D. Anderson Cancer Center |
2009-07-22 | PHASE2 |
| NCT02189343 | COMPLETED | Multiple Myeloma |
Celgene |
2014-09-15 | PHASE1 |
| NCT02384083 | COMPLETED | Multiple Myeloma |
PETHEMA Foundation |
2015-09 | PHASE1; PHASE2 |
| NCT02158702 | UNKNOWN | Multiple Myeloma; Relapse After Use of Lenalidomide and Bortezomib |
National University Hospital, Singapore |
2014-11 | PHASE2 |
| NCT03424928 | COMPLETED | Bioequivalence |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2018-01-19 | PHASE1 |
| NCT02206425 | COMPLETED | Multiple Myeloma |
Oncotherapeutics |
2014-09 | PHASE1; PHASE2 |
| NCT02654132 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2016-03-18 | PHASE2 |
| NCT03023527 | TERMINATED | Multiple Myeloma |
PETHEMA Foundation |
2017-01 | PHASE1 |
| NCT02462525 | TERMINATED | Multiple Myeloma |
AbbVie |
2015-05-06 | PHASE1 |
| NCT01212952 | COMPLETED | Refractory Multiple Myeloma |
Mayo Clinic |
2011-09 | PHASE1; PHASE2 |
| NCT02289222 | TERMINATED | Multiple Myeloma |
Ashraf Badros |
2014-12-30 | PHASE1; PHASE2 |
| NCT01688466 | COMPLETED | Graft vs Host Disease; Graft-Versus-Host Disease |
National Cancer Institute (NCI) |
2012-08-30 | PHASE2 |
| NCT02045017 | COMPLETED | Multiple Myeloma |
Celgene |
2014-02-28 | PHASE2 |
| NCT02578121 | WITHDRAWN | Multiple Myeloma |
University of Arkansas |
2015-12 | PHASE2 |
| NCT02244125 | COMPLETED | Multiple Myeloma; First Relapse |
Institut Curie |
2014-04-14 | PHASE2 |
| NCT00949364 | COMPLETED | Myeloproliferative Neoplasms |
University of Ulm |
2009-12 | PHASE2 |
| NCT01754402 | UNKNOWN | Multiple Myeloma |
Cristina Gasparetto |
2013-01-07 | PHASE1; PHASE2 |
| NCT01510613 | COMPLETED | Primary Amyloidosis of Light Chain Type |
Fondazione IRCCS Policlinico San Matteo di Pavia |
2012-02 | PHASE2 |
| NCT01541332 | UNKNOWN | Multiple Myeloma |
Oncotherapeutics |
2012-02 | PHASE1; PHASE2 |
| NCT01559129 | TERMINATED | Scleroderma, Systemic; Sclerosis, Systemic; Systemic Scleroderma; Systemic Sclerosis; Interstitial Lung Disease |
Celgene |
2012-08-09 | PHASE2 |
| NCT01794039 | COMPLETED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Mayo Clinic |
2014-03 | PHASE2 |
| NCT02103335 | COMPLETED | Multiple Myeloma in Relapse; Refractory Multiple Myeloma; Multiple Myeloma |
Celgene |
2014-06-05 | PHASE1 |
| NCT01979276 | TERMINATED | Multiple Myeloma |
Weill Medical College of Cornell University |
2013-11 | PHASE1; PHASE2 |
| NCT01522872 | UNKNOWN | Multiple Myeloma |
Threshold Pharmaceuticals |
2012-02 | PHASE1; PHASE2 |
| NCT02046915 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
University Hospital Tuebingen |
2014-04 | PHASE2 |
| NCT01432600 | COMPLETED | Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2011-11 | PHASE1; PHASE2 |
| NCT01722305 | COMPLETED | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma; Central Nervous System Lymphoma; Intraocular Lymphoma; Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System; Recurrent Adult Diffuse Large Cell Lymphoma; Retinal Lymphoma |
Mayo Clinic |
2013-04-08 | PHASE1 |
| NCT02119468 | COMPLETED | Refractory Plasma Cell Myeloma; Recurrent Plasma Cell Myeloma |
City of Hope Medical Center |
2014-06-30 | PHASE1; PHASE2 |
| NCT02071888 | COMPLETED | Non-Hodgkin's Lymphoma (NHL); Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM); Other B-cell NHL Subtypes, Including WM; T-cell NHL |
Calithera Biosciences, Inc |
2014-02 | PHASE1 |
| NCT01807286 | TERMINATED | Myeloma |
M.D. Anderson Cancer Center |
2014-01 | PHASE1 |
| NCT01745640 | COMPLETED | Multiple Myeloma |
University Hospital, Lille |
2012-01 | PHASE2 |
| NCT01078974 | TERMINATED | Waldenstrom's Macroglobulinemia |
Steven P. Treon, MD, PhD |
2010-05 | PHASE1 |
| NCT01568294 | COMPLETED | Multiple Myeloma |
Celgene |
2012-04-01 | PHASE1 |
| NCT02185820 | COMPLETED | Multiple Myeloma |
European Myeloma Network B.V. |
2014-06 | PHASE1; PHASE2 |
| NCT01889420 | TERMINATED | Multiple Myeloma in Relapse |
New Mexico Cancer Research Alliance |
2014-07 | PHASE1 |
| NCT01159574 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2010-08 | PHASE2 |
| NCT02228512 | WITHDRAWN | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease; Primary Effusion Lymphoma |
National Cancer Institute (NCI) |
2014-08-15 | PHASE1; PHASE2 |
| NCT01319422 | COMPLETED | Multiple Myeloma |
Yale University |
2011-06 | PHASE2 |
| NCT02168205 | COMPLETED | Healthy Volunteers |
Celgene |
2014-05-30 | PHASE1 |
| NCT02011113 | COMPLETED | Multiple Myeloma |
Celgene Corporation |
2013-12 | PHASE2 |
| NCT01835561 | COMPLETED | Clinical Pharmacology, Healthy Volunteer Study |
Celgene |
2013-03-01 | PHASE1 |
| NCT01324947 | COMPLETED | Multiple Myeloma |
Celgene |
2011-03-01 | PHASE3 |
| NCT01053949 | COMPLETED | Multiple Myeloma |
University Hospital, Lille |
2009-10 | PHASE2 |
| NCT01537861 | TERMINATED | Multiple Myeloma |
Washington University School of Medicine |
2012-06 | EARLY_PHASE1 |
| NCT01986894 | COMPLETED | Clinical Pharmacology, Healthy Volunteer Study |
Celgene |
2013-10-18 | PHASE1 |
| NCT01177735 | COMPLETED | Multiple Myeloma |
University of Arkansas |
2011-10 | PHASE2 |
| NCT01311687 | COMPLETED | Multiple Myeloma |
Celgene |
2011-03-11 | PHASE3 |
| NCT01178281 | COMPLETED | Primary Myelofibrosis; MPN-associated Myelofibrosis |
Celgene |
2010-09-08 | PHASE3 |
| NCT01707407 | COMPLETED | Pharmacology, Clinical; Healthy |
Celgene |
2012-09-01 | PHASE1 |
| NCT01522547 | COMPLETED | Anemia, Sickle Cell |
Celgene |
2007-08-01 | PHASE1 |
| NCT00558896 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Mayo Clinic |
2007-11 | PHASE2 |
| NCT01474330 | COMPLETED | Healthy |
Celgene |
2011-08-01 | PHASE1 |
| NCT01166113 | COMPLETED | Multiple Myeloma |
Fondazione EMN Italy Onlus |
2010-07 | PHASE1; PHASE2 |
| NCT00833833 | COMPLETED | Multiple Myeloma |
Celgene Corporation |
2008-06 | PHASE1; PHASE2 |
| NCT00537511 | TERMINATED | Carcinoma, Small Cell |
Celgene |
2008-02-01 | PHASE1; PHASE2 |
| NCT00770757 | COMPLETED | Graft vs Host Disease |
Washington University School of Medicine |
2009-02 | PHASE2 |
| NCT01135199 | WITHDRAWN | Pulmonary Fibrosis |
Stanford University |
2010-04 | PHASE2 |
| NCT00463385 | COMPLETED | Myelofibrosis With Myeloid Metaplasia; Myeloid Metaplasia; Myelofibrosis |
Celgene |
2007-04-01 | PHASE2 |
| NCT00717522 | TERMINATED | Soft Tissue Sarcoma |
Celgene |
2008-08-01 | PHASE2 |
| NCT00540579 | COMPLETED | Pancreatic Cancer |
SCRI Development Innovations, LLC |
2007-11 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-08-14)
Check the
Pomalidomide (CC-4047)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Pomalidomide (CC-4047) Mechanism of Action: Cereblon Inhibition in Plasma Cell Research
- Pomalidomide (CC-4047) Working Concentration | Cell Culture | Treatment
- Pomalidomide (CC-4047) Solubility in DMSO
- Pomalidomide (CC-4047) Stock Solution
- Pomalidomide (CC-4047) Storage
- Pomalidomide (CC-4047) Stability
- Pomalidomide (CC-4047) Combination Database
- Pomalidomide (CC-4047) Molecular Weight
- Pomalidomide (CC-4047) SMILES
- Pomalidomide (CC-4047) CAS Number
- Pomalidomide (CC-4047) Chemical Structure (2D and 3D)
- Pomalidomide (CC-4047) IC50 for Cell-based and Cell-free Assays
- Pomalidomide (CC-4047) Sigma (P0018)? Try a better option.
- Pomalidomide (CC-4047) MedChemExpress (HY-10984)? Try a better option.
- Pomalidomide (CC-4047) Cayman (19877)? Try a better option.
- Pomalidomide (CC-4047) APExBIO (A4212)? Try a better option.
- Pomalidomide (CC-4047) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.